Recent achievements include:
CEPHALON, INC. V. WATSON PHARM., INC.
In February 2013, the Federal Circuit issued a favorable decision on behalf of our client Cephalon, reversing a district court decision invalidating two patents covering the company's cancer pain medication Fentora. In particular, the Federal Circuit found that the defendant, generic drug manufacturer Watson Pharmaceuticals (now Actavis), "failed as a matter of law to show with clear and convincing evidence that... Read More
VAILLANCOURT V. BECTON DICKINSON & CO.
In February 2013, WilmerHale obtained a significant victory for Becton, Dickinson and Company (BD) in a patent reexamination when the US Patent and Trademark Office (PTO) denied a request for rehearing of an appeal decision in an inter partes reexamination, which had been decided in a manner favorable to BD. This case is the first time BD had used inter partes reexamination as a strategic IP procedure to assure freedom to operate in their desired syringe market.... Read More
CLASSEN IMMUNOTHERAPIES, INC. V. SOMAXON PHARMACEUTICALS
2:12-cv-06643-GAF-PLA, US District Court, Central District of California
In April 2013, the firm achieved victory when Judge Gary Allen Feess of the Central District of California dismissed Classen Immunotherapies, Inc.'s ("Classen") patent infringement claims against our client Somaxon Pharmaceuticals with prejudice. The two asserted Classen patents purport to claim methods of gathering, analyzing, and commercializing adverse event data.... Read More
CELLECTIS SA V. PRECISION BIOSCIENCES
In May 2013, WilmerHale secured a victory for client Precision BioSciences, Inc., a leader in the field of genome engineering, in a patent infringement lawsuit against Cellectis SA. A jury found that all of the claims of Cellectis' US Pat. No. 7,897,372 (the "'372 patent") that were asserted against Precision are invalid both as obvious and for failure to meet the written description requirement and... Read More
BRAINTREE LABORATORIES, INC. V. NOVEL LABORATORIES, INC.
3:11-cv-01341, US District Court, District of New Jersey
In June 2013, WilmerHale obtained a favorable final judgment in the US District Court for the District of New Jersey for Braintree Laboratories, Inc. (Braintree) in its patent infringement case against Novel Laboratories (Novel). The matter involved SUPREP ®—Braintree's small volume sulfate-based colonoscopy preparation product—and Novel's proposed plan to make a generic version of the drug.... Read More
ALTANA PHARMA AG AND WYETH V. TEVA PHARMACEUTICALS
In June 2013, our client Pfizer (formerly Wyeth) announced a $2.15 billion settlement with Teva Pharmaceuticals Industries and Sun Pharmaceutical Industries, which occurred during the trial of Pfizer's and Nycomed's (formerly Altana Pharma AG, and now part of Takeda) claims for patent-infringement damages... Read More
MICROLINC V. INTEL
In July 2013, WilmerHale obtained a zero-dollar walk away settlement on behalf of our client Intel in a patent infringement suit brought by Microlinc, a patent troll, in the Eastern District of Texas. After eight years of litigation, four patent reexaminations, four judges, two lawsuits, and one decisive Markman order, we obtained a statement in the stipulation of dismissal that Microlinc was unable to assert any infringement based on the Court’s claim construction.
ST. CLAIR INTELLECTUAL PROP. CONSULTANTS, INC. V. MATSUSHITA ELECTRIC INDUS. CO.
In July 2013, we obtained a significant victory for Research In Motion (now known as BlackBerry) against non-practicing entity St. Clair Intellectual Property Consultants, Inc. when the Federal Circuit summarily affirmed the district court's summary judgment of non-infringement in RIM's favor. The decision from the Court of Appeals brought to an end a decade-long litigation campaign by St. Clair in which it had won over $100 million in jury verdicts and settlements.
PERMOBIL, INC. V. PRIDE MOBILITY PRODUCTS CORP.
WilmerHale recently achieved a significant victory for client Permobil, Inc. in defense of claims of patent infringement asserted by Pride Mobility Products Corp. in the US District Court for the Eastern District of Pennsylvania. In April 2013, Pride filed suit against Permobil alleging infringement of certain claims of Pride's US Patent No. 8,408,343 (the "'343 patent") and... Read More
@HOME BONDHOLDERS' LIQUIDATING TRUST V. VERIZON COMMUNICATIONS
We achieved a complete victory for our client, Verizon, as the direct result of an extremely favorable claim construction in a large, multi-defendant patent litigation in the Southern District of New York. The plaintiff in the litigation was Richard Williamson, in his capacity as Trustee for the @Home Bondholders' Liquidating Trust. One of the key assets of the bankrupt company was a series of patents directed to the high-speed delivery of media content over existing cable TV systems... Read More
W.L. GORE & ASSOCIATES, INC. V. ATRIUM MEDICAL
On April 2012, W.L. Gore & Associates, Inc. filed suit against our client Atrium Medical Corporation in the US District Court for the District of Arizona, asserting three patents related to stents covered with expanded polytetrafluoroethylene (ePTFE). During its previous litigation against Medtronic, Gore's counsel successfully persuaded the district court to adopt several claim constructions that were favorable for Atrium.... Read More
KODAK V. ALTEK CORPORATION
In October 2013, a jury in SDNY returned a verdict in favor of our client Kodak, resulting in a damages award of $75.8 million. Prior to trial, the Kodak team obtained summary judgment that Ricoh owed royalties on point and shoot cameras. On the eve of trial, Ricoh stipulated to $53 million in damages on point and shoot cameras.... Read More
BROADCOM CORP. V. EMULEX
In October 2013, we achieved a victory for client Broadcom when the Federal Circuit affirmed the district court's issuance of a permanent injunction against Emulex and underlying findings of infringement and validity of Broadcom's '150 patent, which relates to high-speed network communication circuitry.... Read More
Read about our 2012 experience.